Clinical trials: Acromegaly
Acromegaly
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
- Trial name
- NCT00068042
- Testing
- Pegvisomant, Sandostatin LAR
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Acromegaly
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel given in doses titrated to effect in acromegalic patients previously treated or not with somatostatin analogues.
- Trial name
- NCT00210457
- Testing
- Lanreotide (Autogel formulation)
- Where
- 17 sites in France, Switzerland
- Volunteers
- 63 people
- Sponsor
- Ipsen
Acromegaly
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study was to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization…
- Trial name
- NCT00600886
- Testing
- Pasireotide, Octreotide
- Where
- 95 sites in United States, Argentina and 25 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL) therapy.
- Trial name
- NCT03967249
- Testing
- IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL)
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 39 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Acromegaly
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly.
- Trial name
- NCT00128232
- Testing
- Octreotide LAR
- Volunteers
- 100 people
- Sponsor
- Novartis
Acromegaly
A Study to Evaluate MAR002 for Acromegaly
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
- Trial name
- NCT07641179
- Testing
- MAR002
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Marea Therapeutics
Acromegaly
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma.
- Trial name
- NCT00171730
- Testing
- Pasireotide
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Study of MAR002 in Healthy Men
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
- Trial name
- NCT07195175
- Testing
- MAR002
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Marea Therapeutics
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly.
- Trial name
- NCT01412424
- Testing
- Octreotide capsules
- Where
- 36 sites in United States, Germany and 11 more
- Volunteers
- 155 people
- Sponsor
- Chiasma, Inc.
Acromegaly
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.
- Trial name
- NCT00635765
- Testing
- C2L-OCT-01 PR 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 63 people
- Sponsor
- Ambrilia Biopharma, Inc.
Acromegaly
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment…
- Trial name
- NCT03789656
- Testing
- Paltusotine
- Where
- 26 sites in United States, Brazil and 10 more
- Volunteers
- 47 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical…
- Trial name
- HOSCAR (NCT01278342)
- Testing
- Sandostatin LAR, pegvisomant, cabergoline
- Where
- 20 sites in France, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.
- Trial name
- NCT00372697
- Testing
- Octreotide acetate 30 mg suspension
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with…
- Trial name
- NCT00517491
- Testing
- lanreotide (Autogel formulation)
- Where
- Mexico
- Sponsor
- Ipsen